BRPI0509978A - uso de padrão proteÈmico de plasma para diagnóstico, classificação, previsão de resposta à terapia e comportamento clìnico, estratificação de terapia, e monitoramento de doença em malignidades hematológicas - Google Patents

uso de padrão proteÈmico de plasma para diagnóstico, classificação, previsão de resposta à terapia e comportamento clìnico, estratificação de terapia, e monitoramento de doença em malignidades hematológicas

Info

Publication number
BRPI0509978A
BRPI0509978A BRPI0509978-1A BRPI0509978A BRPI0509978A BR PI0509978 A BRPI0509978 A BR PI0509978A BR PI0509978 A BRPI0509978 A BR PI0509978A BR PI0509978 A BRPI0509978 A BR PI0509978A
Authority
BR
Brazil
Prior art keywords
therapy
prediction
diagnosis
protein
plasma
Prior art date
Application number
BRPI0509978-1A
Other languages
English (en)
Inventor
Maher Albitar
Elihu H Estey
Hagop M Kantarjian
Francis J Giles
Michael J Keating
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BRPI0509978A publication Critical patent/BRPI0509978A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25625—Dilution

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

USO DE PADRãO PROTEÈMICO DE PLASMA PARA DIAGNóSTICO, CLASSIFICAçãO, PREVISãO DE RESPOSTA à TERAPIA E COMPORTAMENTO CLìNICO, ESTRATIFICAçãO DE TERAPIA, E MONITORAMENTO DE DOENçA EM MALIGNIDADES HEMATOLóGICAS. A presente invenção demonstra que o diagnóstico e a previsão de comportamento clínico em pacientes com malignidade hematológica, tais como leucemia, podem ser realizados pela análise de proteínas presentes na amostra de plasma. Portanto, em modalidades particulares a presente invenção utiliza plasma para criar ou prognosticar o perfil de proteínas da malignidade hematológica, que compreende a coleta de amostras de plasma de uma população de pacientes com malignidades hematológicas; geração de um espectro de proteínas de amostras de plasma com ou sem fracionamento; comparação do espectro de proteínas com os dados clínicos; e identificação de marcadores protéicos nas amostras de plasma que correlacionam com dados clínicos. Os maçadores protéicos identificados por esta abordagem podem, então, ser utilizados para criar um perfil de proteínas que pode ser utilizado para diagnosticar a malignidade hematológica ou determinar o prognóstico da malignidade hematológica.
BRPI0509978-1A 2004-04-20 2005-04-20 uso de padrão proteÈmico de plasma para diagnóstico, classificação, previsão de resposta à terapia e comportamento clìnico, estratificação de terapia, e monitoramento de doença em malignidades hematológicas BRPI0509978A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56387304P 2004-04-20 2004-04-20
PCT/US2005/013224 WO2005103719A2 (en) 2004-04-20 2005-04-20 Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies

Publications (1)

Publication Number Publication Date
BRPI0509978A true BRPI0509978A (pt) 2007-10-16

Family

ID=35094386

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509978-1A BRPI0509978A (pt) 2004-04-20 2005-04-20 uso de padrão proteÈmico de plasma para diagnóstico, classificação, previsão de resposta à terapia e comportamento clìnico, estratificação de terapia, e monitoramento de doença em malignidades hematológicas

Country Status (7)

Country Link
US (3) US7622306B2 (pt)
EP (2) EP2221618A3 (pt)
JP (1) JP4864875B2 (pt)
BR (1) BRPI0509978A (pt)
CA (1) CA2563847A1 (pt)
MX (1) MXPA06012232A (pt)
WO (1) WO2005103719A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008020B2 (en) * 2004-06-03 2011-08-30 Vermillion, Inc. Biomarkers for peripheral artery disease
US20070042443A1 (en) 2005-08-17 2007-02-22 Quest Diagnostics Investments Incorporated Hematopoietic cell phenotyping using free circulating cellular markers
JP2007240326A (ja) * 2006-03-08 2007-09-20 Intec Web & Genome Informatics Corp 波形解析装置
US20100140465A1 (en) * 2006-03-29 2010-06-10 Chulso Moon Apparatus and Method for Filtration to Enhance the Detection of Peaks
US20100055723A1 (en) * 2007-01-23 2010-03-04 University Of Virginia Patent Foundation Galectin-3-Binding Protein as a Biomarker of Cardiovascular Disease
WO2009022173A1 (en) * 2007-08-14 2009-02-19 Petscreen Limited Novel diagnostic methods
KR100937720B1 (ko) * 2009-04-20 2010-01-20 전남대학교산학협력단 ＣＦＨ 또는 ＡｐｏＨ를 급성골수성백혈병 관해 진단용 생화학적 마커로 사용하는 방법
KR101997543B1 (ko) * 2010-07-30 2019-07-09 이엠디 밀리포어 코포레이션 크로마토그래피 매질 및 방법
ES2877563T3 (es) 2014-09-02 2021-11-17 Emd Millipore Corp Medios de cromotografía que comprenden conjuntos porosos discretos de nanofibrillas
US20170298091A1 (en) 2014-12-08 2017-10-19 Emd Millipore Corporation Mixed Bed Ion Exchange Adsorber
JP6565801B2 (ja) * 2016-06-23 2019-08-28 株式会社島津製作所 質量分析データ処理装置、質量分析装置、質量分析データ処理方法、及び質量分析データ処理用プログラム
CN109507347B (zh) * 2017-09-14 2021-01-29 湖南中烟工业有限责任公司 一种色谱峰选择方法
US11096582B2 (en) * 2018-11-20 2021-08-24 Veris Health Inc. Vascular access devices, systems, and methods for monitoring patient health
CN110632191B (zh) * 2019-09-10 2023-04-18 福建工程学院 一种基于决策树算法的变压器色谱峰定性方法和系统
EP4198511A1 (en) * 2021-12-17 2023-06-21 Lehtio, Janne Method for determining aml prognosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534121A (en) 1994-05-16 1996-07-09 The United States Of America As Represented By The Department Of Health And Human Services Preparative two dimensional gel electrophoresis system
JP2002523776A (ja) 1998-08-31 2002-07-30 シー．ビー．エス．サイエンティフィック カンパニー，インコーポレイティド 二次元ゲル電気泳動システム
IN191209B (pt) 1999-09-08 2003-10-04 Council Scient Ind Res
EP1386275A2 (en) * 2000-07-18 2004-02-04 Correlogic Systems, Inc. A process for discriminating between biological states based on hidden patterns from biological data
AUPQ886100A0 (en) * 2000-07-19 2000-08-10 Biotron Limited Diagnostic test
US20030013120A1 (en) * 2001-07-12 2003-01-16 Patz Edward F. System and method for differential protein expression and a diagnostic biomarker discovery system and method using same
US20060204958A1 (en) * 2002-05-17 2006-09-14 Eastern Virginia Medical School Methods for diagnosing htlv-i-mediated diseases

Also Published As

Publication number Publication date
MXPA06012232A (es) 2007-06-15
WO2005103719A3 (en) 2005-12-15
US8097468B2 (en) 2012-01-17
WO2005103719A2 (en) 2005-11-03
CA2563847A1 (en) 2005-11-03
JP2007533997A (ja) 2007-11-22
US8563323B2 (en) 2013-10-22
US20120145891A1 (en) 2012-06-14
EP2221618A2 (en) 2010-08-25
EP1756578A2 (en) 2007-02-28
US20100063747A1 (en) 2010-03-11
EP2221618A3 (en) 2010-09-01
US20060073527A1 (en) 2006-04-06
US7622306B2 (en) 2009-11-24
JP4864875B2 (ja) 2012-02-01

Similar Documents

Publication Publication Date Title
BRPI0509978A (pt) uso de padrão proteÈmico de plasma para diagnóstico, classificação, previsão de resposta à terapia e comportamento clìnico, estratificação de terapia, e monitoramento de doença em malignidades hematológicas
Proctor et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study
Mowbray et al. A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection
Smith et al. Biomarkers in dysplasia of the oral cavity: a systematic review
Distler et al. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas–a retrospective tumor marker prognostic study
BR112014006432A2 (pt) biomarcadores do câncer de pulmão e seus usos
Seidel et al. Modified nucleosides as biomarkers for early cancer diagnose in exposed populations
Pelaia et al. Application of proteomics and peptidomics to COPD
BRPI0618713B8 (pt) cardiolipina modificada e seus usos
Rouprêt et al. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis
Wang et al. Comparative proteome analysis of peripheral blood mononuclear cells in systemic lupus erythematosus with iTRAQ quantitative proteomics
Mangé et al. An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma
BR0317394A (pt) Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal
EA201370063A1 (ru) Фосфолипидом рака
Zhu et al. Serum proteomic profiling for the early diagnosis of colorectal cancer
Lee et al. Development and validation of a novel plasma protein signature for breast cancer diagnosis by using multiple reaction monitoring-based mass spectrometry
WO2008048508A3 (en) Prognostic biomarkers in patients with ovarian cancer
BRPI0614151A2 (pt) métodos para determinar quais os membros, individualmente ou em combinação, de um conjunto elementar de testes intermediários são preditivos de um conjunto elementar de resultados de teste de uso final, para prever se uma amostra candidato atenderá ao conjunto elementar de resultados de teste de uso final, para prever se uma amostra de lubrificante candidato será aprovada em um teste de uso final escolhido para lubrificantes, para determinar qual a combinação de membros de um conjunto elementar de testes intermediários que tem uma correlação elevada com um conjunto elementar de resultados de teste de uso final e para escolher componentes e quantidades de componentes em lubrificantes, fluidos funcionais ou graxas
Righi et al. Histological response to neoadjuvant chemotherapy in localized Ewing sarcoma of the bone: A retrospective analysis of available scoring tools
Sun et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma
BR112015021507A2 (pt) métodos e composições para o diagnóstico de pré-eclampsia
Fleming et al. New RNA methods for the identification of body fluids and cell types
Matharoo‐Ball et al. Serum biomarker profiling in cancer studies: a question of standardisation?
BRPI0518633A2 (pt) processo para estimar os resÍduos provocados por estoques de abastecimento de refinarias
McKiernan et al. NextGen serology: leveraging mass spectrometry for Protein-Based human body fluid identification

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.